The black box warnings concerning teens and young adults taking antidepressants include:

Lithium is a narrow therapeutic index medication commonly used for bipolar disorder to stabilize mood and prevent manic and depressive episodes. Because the difference between therapeutic and toxic levels is small, patients require careful monitoring of serum levels, renal function, and clinical symptoms. Toxicity can develop gradually or suddenly and may be triggered by dehydration, drug interactions, or impaired renal clearance. Early recognition of toxicity signs is critical to prevent serious neurologic and systemic complications.

Rationale:
A. A new or worsening tremor is an early sign of lithium toxicity. With Lithium, mild fine tremors may occur at therapeutic levels, but progression to coarse tremors suggests increasing serum concentration and potential toxicity. This symptom reflects early neuromuscular involvement and requires prompt evaluation of serum lithium levels.

B. Nausea and vomiting are common gastrointestinal manifestations of lithium toxicity. As serum levels of Lithium rise, GI irritation occurs early and may precede more severe neurologic symptoms. These symptoms should not be dismissed as routine side effects when they are persistent or worsening.

C. Confusion is a serious neurologic sign of lithium toxicity indicating central nervous system involvement. Elevated levels of Lithium can impair cognitive function, leading to disorientation, lethargy, and in severe cases, seizures or coma. This is a late and potentially life-threatening manifestation requiring urgent intervention.

D. All options are correct because tremor, nausea/vomiting, and confusion are all recognized clinical signs of lithium toxicity. With Lithium, toxicity affects multiple body systems including gastrointestinal, neurologic, and neuromuscular systems. Recognizing the full spectrum of symptoms is essential for early detection and prevention of severe complications.

Combined oral contraceptives (COCs) contain estrogen and progestin components that influence both contraceptive efficacy and side effect profiles. Androgenic side effects such as acne and weight changes are commonly associated with second-generation progestins due to their higher androgen receptor activity. Selecting an alternative formulation often involves switching to a progestin with lower androgenic activity while maintaining adequate cycle control and contraceptive effectiveness. The goal is to improve tolerability without compromising safety or efficacy.

Rationale:
A. Androgenic side effects from Levonorgestrel do not reliably resolve over time in many patients, especially when related to intrinsic androgen receptor activity. Waiting without changing therapy may prolong bothersome acne and weight concerns, reducing adherence and satisfaction. Clinical improvement is more likely achieved through changing the progestin component rather than expecting spontaneous resolution.

B. Lowering the ethinyl estradiol (EE) dose while continuing Levonorgestrel may reduce estrogen-related side effects but does not significantly address androgenic effects such as acne. In some cases, reducing estrogen may worsen breakthrough bleeding without improving acne. Therefore, this option does not effectively target the patient’s main concern.

C. A progesterone-only contraceptive such as Norethindrone is not appropriate in this scenario because it eliminates estrogen, which plays a role in cycle regulation and acne control. Progestin-only pills can also cause irregular bleeding and may not improve androgenic side effects. This option does not optimize both safety and symptom management for the patient’s presentation.

D. Switching to a formulation containing Desogestrel while maintaining EE 30mcg is the best option because third-generation progestins have lower androgenic activity compared to levonorgestrel. This change is more likely to improve acne and weight-related concerns while maintaining good cycle control and contraceptive efficacy. It balances symptom management with continued reliable contraception.